Antipsychotic drugs, dopamine D2 receptors, and schizophrenia

Neurotransmitter Receptors in Actions of Antipsychotic Medications

Volumn , Issue , 2000, Pages 43-63

  Seeman, Philip ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0002103527     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (88)

1. Seeman, P., Wong, M., and Lee, T., Dopamine receptor-block and nigral fiber-impulse blockade by major tranquilizers, Fed. Proc., 33, 246, 1974.
2. Seeman, P., Chau-Wong, M., Tedesco, J., and Wong, K., Brain receptors for antipsychotic drugs and dopamine: direct binding assays, Proc. Natl. Acad. Sci. U.S.A., 72, 4376, 1975.
3. Seeman, P., Lee, T., Chau-Wong, M., and Wong, K., Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature, 261, 717, 1976.
4. 3H]dopamine binding associated with dopamine receptors in calf brain membranes, Mol. Pharmacol., 12, 800, 1976.
5. Seeman, P., Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2, clozapine occupies D4, Neuropsychopharmacology, 7, 261, 1992.
6. Seeman, P., Therapeutic receptor-blocking concentrations of neuroleptics, Int. Clin. Psychopharmacol., 10 (Suppl. 3), 5, 1995.
7. Seeman, P., Corbett, R., Nam, D., and Van Tol, H.H.M., Dopamine and serotonin receptors: amino acid sequences, and clinical role in neuroleptic Parkinsonism, Jpn. J. Pharmacol., 71, 187, 1996.
8. Seeman, P., Corbett, R., and Van Tol, H.H.M., Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4, Neuropsychopharmacology, 16, 91, 1996.
9. Seeman, P. and Tallerico, T., Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors, Mol. Psychiatry, 3, 123, 1998.
10. 4 receptor varies with the affinity of the competing radioligand, Eur. J. Pharmacol. Mol. Pharmacol. Sect., 291, 59, 1995.
11. Nordin, C., Almé, B., and Bondesson, U., CSF and serum concentrations of clozapine and its demethyl metabolite: a pilot study, Psychopharmacology, 122, 104, 1995.
12. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine, Arch. Gen. Psychiatry, 49, 538, 1992.
13. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients, Am. J. Psychiatry, 152, 1444, 1995.
14. Nyberg, S., Nordström, A.-L., Halldin, C., and Farde, L., Positron emission tomography studies on D2 dopamine receptor occupancy and plasma antipsychotic drug levels in man, Int. Clin. Psychopharmacol., 10 (Suppl. 3), 81, 1995.
15. 2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study, Life Sci., 57, PL103, 1995.
16. 2 receptor occupancy with low-dose haloperidol treatment: a PET study, Am. J. Psychiatry, 153, 948, 1996.
17. 2 receptor occupancy profile of loxapine determined using PET, Neuropsychopharmacology, 15, 562, 1996.
18. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation, Am. J. Psychiatry, 155, 921, 1998.
19. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia, Am. J. Psychiatry, 156, 286, 1999.
20. Knable, M.B., Heinz, A., Coppola, R., Gorey, J., and Weinberger, D.R., IBZM SPECT measurement of D2 receptor occupancy by haloperidol and risperidone, Biol. Psychiatry, 39 (Abstr.), 515, 1996.
21. Kawagoe, K.T., Garris, P.A., Wiedemann, D.J., and Wightman, R.M., Regulation of transient dopamine concentration gradients in the microenvironment surrounding nerve terminals in the rat striatum, Neuroscience, 51, 55, 1992.
22. George, S.R., Watanabe, M., Di Paolo, T., Falardeau, P., Labrie, F., and Seeman, P., The functional state of the dopamine receptor in the anterior pituitary is in the high-affinity form, Endocrinology, 117, 690, 1985.
23. Farde, L. and Nordström, A.-L., PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients, Br. J. Psychiatry, 160 (Suppl. 17), 30, 1992.
24. Tauscher, J., Küfferle, B., Barnas, C., Asenbaum, S., Brücke, T., and Kasper, S., Dopamine-2 receptor imaging in psychotic patients treated with quetiapine, clozapine, risperidone and haloperidol, Biol. Psychiatry, 42, 15S, 1997.
25. Küfferle, B., Tauscher, J., Asenbaum, S., Vesely, C., Podreka, I., Brücke, T., and Kasper, S., IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol, Psychopharmacology, 133, 323, 1997.
26. Nordström, A.-L., Farde, L., Wiesel, F.-A., Forslund, K., Pauli, S., Halldin, C., and Uppfeldt, G., Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients, Biol. Psychiatry, 33, 227, 1993.
27. 2 receptor occupancy of ziprasidone in healthy volunteers, Am. Coll. Neuropsychopharmacol. Abstr., 35, 269, 1996.
28. 2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography, Psychopharmacology, 124, 141, 1996.
29. Kasper, S., Tauscher, J., Küfferle, B., Asenbaum, S., Barnas, C., Hesselmann, B., Podreka, I., and Brücke, T., Sertindole and dopamine D2 receptor occupancy, Biol. Psychiatry, 42, 161S, 1997.
30. 2 receptor occupancy in comparison to risperidone, clozapine and haloperidol, Psychopharmacology, 136, 367, 1998.
31. 2 receptors: implications for the therapeutics of schizophrenia, Am. J. Psychiatry, 154, 1525, 1997.
32. 123I-IBZM single photon emission tomography (SPET) study, Psychopharmacology, 117, 55, 1995.
33. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics, Am. J. Psychiatry, 153, 183, 1996.
34. Scherer, J., Tatsch, K., Schwarz, J., Oertel, W.H., Konjarczyk, M., and Albus, M., D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects, Acta Psychiatr. Scand., 90, 266, 1994.
35. 123I IBZM single photon emission tomography (SPET) study, Psychopharmacology, 124, 148, 1996.
36. Su, T.-P., Breier, A., Coppola, R., Hadd, K., Elman, I., Adler, C., Malhotra, A.K., Watsky, E., Gorey, J., Weinberger, D., and Pickar, D., D2 receptor occupancy in risperidone and clozapine-treated schizophrenics, Biol. Psychiatry, 39, 512, 1996.
37. Su, T.-P., Breier, A., Coppola, R., Hadd, K., Elman, I., Alder, C., Malhotra, A.K., Watsky, E., Gorey, J., Hough, C.J., Weinberger, D., and Pickar, D., D2 receptor occupancy during risperidone and clozapine treatment in chronic schizophrenia: relationship to blood level, efficacy and EPS, Soc. Neurosci. Abstr., 22, 265, 1996.
38. 2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients, Arch. Gen. Psychiatry, 54, 972, 1997.
39. Gefvert, O., Lundberg, T., Wieselgren, I.-M., Hagström, P., Bergström, M., Långström, B., Wiesel, F.-A., Yates, R., and Lindström, L.H., D2 and 5HT2A receptor binding of different doses of quetiapine in schizophrenics: a PET study, Am. Coll. Neuropsychopharmacol. Abstr., 36, 168, 1997.
40. 2 dopamine receptor binding differences of clozapine and haloperidol, J. Neural Transm., 86, 163, 1991.
41. 18FESP, in New Generation of Antipsychotic Drugs: Novel Mechanisms of Action, Vol. 4, Brunello, N., Mendlewicz, J., and Racagni, G., Eds., International Academy of Biomedical Drug Research, S. Karger, Basel, 1993, 130.
42. Louwerens, J.W., Slooff, C.J., Korf, J., Coppens, H.J., and Paans, A.M.J., Dopamine2-and serotonin2-receptor-antagonism by antipsychotics in man, Schizophr. Res., 18 (Abstr.), 141, 1996.
43. 11C NMSP receptor occupancy by clozapine and haloperidol in schizophrenic subjects, Schizophr. Res., 15 (Abstr.), 80, 1995.
44. 11C NMSP receptor occupancy by clozapine and haloperidol in schizophrenic subjects, Biol. Psychiatry, 39 (Abstr.), 513, 1996.
45. 2 dopamine receptor occupancy in clozapine-treated patients, Am. J. Psychiatry, 153, 1571, 1996.
46. Brunello, N., Masotto, C., Steardo, L., Markstein, R., and Racagni, G., New insights into the biology of schizophrenia through the mechanism of action of clozapine, Neuropsychopharmacology, 13, 177, 1995.
47. Seeman, P. and Kapur, S., Clozapine occupies high levels of dopamine D2 receptors, Life Sci., 60, 207, 1997.
48. 2 receptors: an explanation for low receptor occupancy and early clinical relapse upon drug withdrawal of clozapine or quetiapine, Am. J. Psychiatry, 156, 876, 1999.
49. Pilowsky, L.S., Mulligan, R.S., Acton, P.D., Ell, P.J., Costa, D.C., and Kerwin, R.W., Limbic selectivity of clozapine, Lancet, 350, 490, 1997.
50. Seeman, P., Guan, H.-C., and Niznik, H.B., Endogenous dopamine lowers the dopamine D2 receptor density as measured by [3H]raclopride: implications for positron emission tomography of the human brain, Synapse, 3, 96, 1989.
51. Laruelle, M., De Souza, C., Baldwin, R.M., Abi-Dargham, A., Bowers, M., Seibyl, J.P., Charney, D.S., and Innis, R.B., SPECT measurement of human striatal synaptic dopamine concentration in the resting state, Soc. Neurosci. Abstr., 22 (Abstr.), 266, 1996.
52. Laruelle, M., Abi-Dargham, A., van Dyck, C.H., Gil, R., De Souza, C.D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S.S., Baldwin, R.M., Seibyl, J.P., Krystal, J.H., Charney, D.S., and Innis, R.B., Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug free schizophrenic subjects, Proc. Natl. Acad. Sci. U.S.A., 93, 9235, 1996.
53. 2 receptor occupancy by endogenous dopamine in humans, Neuropsychopharmacology, 17, 162, 1997.
54. Kalkman, H.O., Neumann, V., and Tricklebank, M.D., Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats, Naunyn-Schmiedeberg’s Arch. Pharmakol., 355, 361, 1997.
55. 2 receptor occupancy induced by risperidone in schizophrenic patients, Am. Coll. Neuropsychopharmacol., 35 (Abstr.), 184, 1996.
56. 2 receptor occupancy studies and clinical response, Br. J. Psychiatry, 168, 40, 1996.
57. 2 receptor blocking agent, ritanserin, in the rat, Eur. Neuropsychopharmacol., 6, 305, 1996.
58. 2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release, Psychopharmacology, 131, 57, 1997.
59. Farde, L., Nyberg, S., Nordström, A.-L., Halldin, C., and Sedvall, G., Dopamine and serotonin receptor occupancy examined by PET in antipsychotic drug treated patients, Am. Coll. Neuropsychopharmacol., 32 (Abstr.), 38, 1993.
60. Kane, J., Honigfeld, G., Singer, J., Meltzer, H.Y., and the Clozaril Collaborative Study Group, Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine, Arch. Gen. Psychiatry, 45, 789, 1988.
61. Scurlock, H.J. and Robinson, P.H., Case report 2: remoxipride in resistant schizophrenia, J. Drug Dev., 6, 71, 1993.
62. Scurlock, H.J., Singh, A.N., and Catalan, J., Atypical antipsychotic drugs in the treatment of manic syndromes in patients with HIV-1 infection, J. Psychopharmacol., 9, 151, 1995.
63. Vartianen, H., Leinonen, E., Putkonen, A., Lang, S., Hagert, U., and Tolvanen, U., A long-term study of remoxipride in chronic schizophrenic patients, Acta Psychiatr. Scand., 87, 114, 1993.
64. Shore, D., Matthews, S., Cott, J., and Lieberman, J.A., Clinical implications of clozapine discontinuation: report of an NIMH workshop, Schizophr. Bull., 21, 333, 1995.
65. Meltzer, H.Y., Lee, M.A., Ranjan, R., Mason, E.A., and Cola, P.A., Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine, Psychopharmacology, 124, 176, 1996.
66. 123I-IBZM SPECT following clozapine dose reduction, Schizophr. Res., 15 (Abstr.), 96, 1995.
67. Baron, J.C., Martinot, J.L., Cambon, H., Boulenger, J.P., Poirier, M.F., Caillard, V., Blin, J., Huret, J.D., Loc’h, C., and Maziere, B., Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels, Psychopharmacology, 99, 463, 1989.
68. Friedman, J.H. and Lannon, M.C., Clozapine in the treatment of psychosis in Parkinson’s disease, Neurology, 39, 1219, 1989.
69. Pfeiffer, R.F., Kang, J., Graber, B., Hofman, R., and Wilson, J., Clozapine for psychosis in Parkinson’s disease, Movement Disord., 5, 239, 1990.
70. Kahn, N., Freeman, A., Juncos, J.L., Manning, D., and Watts, R.L., Clozapine is beneficial for psychosis in Parkinson’s disease, Neurology, 41, 1699, 1991.
71. Factor, S.A. and Brown, D., Clozapine prevents recurrence of psychosis in Parkinson’s disease, Movement Disord., 7, 125, 1992.
72. Rabey, J.M., Treves, T.A., Neufeld, M.Y., Orlov, E., and Korczyn, A.D., Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson’s disease, Neurology, 45, 432, 1995.
73. Sandor, P., Lang, A.E., Singal, S., and Angus, C., Remoxipride in the treatment of levodopa-induced psychosis, J. Clin. Psychopharmacol., 16, 395, 1996.
74. Meltzer, H.Y., Kennedy, J., Dai, J., Parsa, M., and Riley, D., Plasma clozapine levels and the treatment of L-DOPA-induced psychosis in Parkinson’s disease. A high potency effect of clozapine, Neuropsychopharmacology, 12, 39, 1995.
75. Seeman, P., Guan, H.-C., and Van Tol, H.H.M., Dopamine D4 receptors elevated in schizophrenia, Nature, 365, 441, 1993.
76. 2 dopamine receptors in drug-naive schizophrenics, Science, 234, 1558, 1986.
77. 11C]N-methylspiperone, Psychiatr. Res. Neuroimaging, 61, 67, 1995.
78. Farde, L., Wiesel, F.-A., Stone-Elander, S., Halldin, C., Nordström, A.-A., Hall, H., and Sedvall, G., D2 dopamine receptors in neuroleptic-naive schizophrenic patients, Arch. Gen. Psychiatry, 47, 213, 1990.
79. Zawarynski, P., Tallerico, T., Seeman, P., Lee, S.P., O’Dowd, B.F., and George, S.R., Dopamine D2 receptor dimers in human and rat brain, FEBS Letts., 441, 383, 1998.
80. Ng, G.Y.K., O’Dowd, B.F., Caron, M., Dennis, M., Brann, M.R., and George, S.R., Phosphorylation and palmitoylation of the human D2L dopamine receptor in Sf9 cells, J. Neurochem., 63, 1589, 1994.
81. Ng, G.Y.K., O’Dowd, B.F., Lee, S.P., Chung, H.T., Brann, M.R., Seeman, P., and George, S.R., Dopamine D2 receptor dimers and receptor-blocking peptides, Biochem. Biophys. Res. Commun., 227, 200, 1996.
82. L receptor to desensitization accompanies the up-regulation of receptors on to the surface of Sf9 cells, Endocrinology, 138, 4199, 1997.
83. Wong, D.F., Gjedde, A., Reith, J., Grunder, G., Szymanski, S., Yokoi, F., Hong, C., Nestadt, G., Neufeld, K., Pearlson, G., Tune, L., and Angrist, B., Imaging intrasynaptic postsynaptic and presynaptic dopamine function in psychosis, Soc. Neurosci. Abstr., 23, 1405, 1997.
84. 3H]spiperone binding in vivo in rat brain, J. Receptor Res., 11, 163, 1991.
85. Abi-Dargham, A., Kegeles, L., Zea-Ponce, Y., Printz, D., Rodenhiser, J., Weiss, R., Mann, J., Gorman, J., Van Heertum, R., and Laruelle, M., Baseline dopamine synaptic concentration is increased in schizophrenia and related to treatment response, Soc. Neurosci. Abstr., 24, 525, 1998.
86. Breier, A., Su, T.-P., Saunders, R., Carson, R.E., Kolachana, B.S., De Bartolomeis, A., Weinberger, D.R., Weisenfeld, N., Malhotra, A.K., Eckelman, W.C., and Pickar, D., Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method, Proc. Natl. Acad. Sci. U.S.A., 94, 2569, 1997.
87. Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R.M., Seibyl, J.P., Bowers, M., van Dyck, C.H., Charney, D.S., Innis, R.B., and Laruelle, M., Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort, Am. J. Psychiatry, 155, 761, 1998.
88. Seeman, P., Niznik, H.B., Guan, H.-C., Booth, G., and Ulpian, C., Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain, Proc. Natl. Acad. Sci. U.S.A., 86, 10156, 1989.